Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Background Enfortumab vedotin (EV) is an antibody‐drug conjugate showing significant overall survival (OS) benefit versus chemotherapy for patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC) in EV‐301. This subgroup analysis was conducted to further analyze...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer medicine (Malden, MA) Jg. 12; H. 3; S. 2761 - 2771
Hauptverfasser:	Matsubara, Nobuaki, Yonese, Junji, Kojima, Takahiro, Azuma, Haruhito, Matsumoto, Hiroaki, Powles, Thomas, Rosenberg, Jonathan E., Petrylak, Daniel P., Matsangou, Maria, Wu, Chunzhang, Campbell, Mary, Yamashiro, Mayumi
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States John Wiley & Sons, Inc 01.02.2023 John Wiley and Sons Inc Wiley
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use antibody‐drug conjugate Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bladder cancer Cancer therapies Carcinoma, Transitional Cell - pathology Cell cycle Chemotherapy Diabetes Drug dosages East Asian People enfortumab vedotin FDA approval Humans Japanese Metastases Metastasis metastatic Monoclonal antibodies Paclitaxel Patients Population Population studies Safety Scintigraphy Survival Targeted cancer therapy Urinary Bladder Neoplasms - pathology Urothelial carcinoma United States > US Japan antibody-drug conjugate urothelial carcinoma metastatic Japanese enfortumab vedotin
ISSN:	2045-7634, 2045-7634
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!